Business Context and Reporting Period
This Form 8-K, filed on November 25, 2023, reports a material definitive agreement entered into by Personalis, Inc. (PSNL) with Tempus Labs, Inc. (Tempus). The filing details a five-year Commercialization and Reference Laboratory Agreement focused on the marketing and clinical validation of Personalis's NeXT Personal Dx assay in the United States.
Key Financial Metrics and Transaction Terms
The filing does not provide historical revenue, profit, cash flow, or balance sheet metrics. Financial terms are specific to the new agreement:
- Market Development Fees: Tempus will pay up to $12,000,000 in aggregate, consisting of a $3,000,000 activation fee, a $3,000,000 first milestone fee, and up to $6,000,000 in second milestone fees payable in quarterly installments.
- Commercialization Compensation: Personalis will compensate Tempus up to $9,600,000 for promotional and commercialization services.
- Revenue Share: Tempus will pay Personalis 10% to 20% of gross revenue if Tempus licenses genomic data derived from the assay to third parties.
- Equity Issuance: Personalis issued two warrants to Tempus to purchase a total of 9,218,800 shares of common stock.
Material Changes and Transaction Structure
The primary material change is the strategic partnership with Tempus, which alters Personalis's commercialization strategy for its NeXT Personal Dx assay.
- Exclusivity: Tempus has exclusive rights to market the assay in breast cancer, lung cancer, and immuno-oncology monitoring indications until December 31, 2027, subject to exceptions.
- Warrant Details:
- First Warrant: 4,609,400 shares at $1.50/share, expiring December 31, 2024.
- Second Warrant: 4,609,400 shares at $2.50/share, expiring December 31, 2025.
- Refund Provisions: If Personalis fails to achieve specific clinical validation milestones or schedules, it must refund Market Development Fees (excluding the Activation Fee) to Tempus.
Guidance, Risks, and Contingencies
Management commentary is limited to the terms of the agreement and standard forward-looking statement disclaimers.
- Performance Risks: The agreement is contingent on Personalis achieving clinical validation milestones. Failure to do so may result in fee refunds, termination, or conversion to a non-exclusive arrangement.
- Reimbursement Risk: Success depends on Personalis's ability to generate evidence to seek reimbursement from payors for the new indications.
- Commercial Risk: Tempus is obligated to use commercially reasonable efforts to market the assay, but commercial success is not guaranteed.
- Termination: Either party may terminate for material breach or insolvency. After the first anniversary, either party may terminate for convenience with 18 months' notice.
Investor Verification Checklist
- Verify the specific clinical validation milestones required to trigger the $9,000,000 in milestone fees.
- Confirm the timeline for the filing of the registration statement for the resale of warrant shares (required within 30 days of issuance).
- Review the "Forward-Looking Statements" section for specific risks regarding reimbursement and third-party performance.
- Monitor the impact of the $9,600,000 commercialization compensation on Personalis's future cash flow and operating expenses.
- Check for any subsequent filings regarding the achievement of the first milestone or changes to the exclusivity terms.